Cargando…

A dynamic N(6)-methyladenosine methylome regulates intrinsic and acquired resistance to tyrosine kinase inhibitors

N(6)-methyladenosine (m(6)A) on mRNAs is critical for various biological processes, yet whether m(6)A regulates drug resistance remains unknown. Here we show that developing resistant phenotypes during tyrosine kinase inhibitor (TKI) therapy depends on m(6)A reduction resulting from FTO overexpressi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yan, Fei, Al-Kali, Aref, Zhang, Zijie, Liu, Jun, Pang, Jiuxia, Zhao, Na, He, Chuan, Litzow, Mark R., Liu, Shujun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6218444/ https://www.ncbi.nlm.nih.gov/pubmed/30297871 http://dx.doi.org/10.1038/s41422-018-0097-4

Ejemplares similares

A nucleolin-DNMT1 regulatory axis in acute myeloid leukemogenesis
por: Shen, Na, et al.
Publicado: (2014)

Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axis
por: Yang, Xiaojuan, et al.
Publicado: (2016)

A regulatory circuit composed of DNA methyltransferases and receptor tyrosine kinases controls lung cancer cell aggressiveness
por: Yan, Fei, et al.
Publicado: (2017)

REPIC: a database for exploring the N(6)-methyladenosine methylome
por: Liu, Shun, et al.
Publicado: (2020)

Elevated Cellular PD1/PD-L1 Expression Confers Acquired Resistance to Cisplatin in Small Cell Lung Cancer Cells
por: Yan, Fei, et al.
Publicado: (2016)

Advances in studies of tyrosine kinase inhibitors and their acquired resistance
por: Jiao, Qinlian, et al.
Publicado: (2018)

Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor
por: Fujino, Toshio, et al.
Publicado: (2021)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
por: Xu, Haiyuan, et al.
Publicado: (2019)

Analysis of N(6)-Methyladenosine Methylome in Adenocarcinoma of Esophagogastric Junction
por: Huang, Jia-Bin, et al.
Publicado: (2022)

Evolutionary Implications of the RNA N(6)-Methyladenosine Methylome in Plants
por: Miao, Zhenyan, et al.
Publicado: (2021)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
por: Ababneh, Obada, et al.
Publicado: (2022)

Comprehensive analysis of differences in N6-methyladenosine RNA methylomes in Helicobacter pylori infection
por: Li, Huan, et al.
Publicado: (2023)

Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
por: Santoni-Rugiu, Eric, et al.
Publicado: (2019)

Acquired cancer tyrosine kinase inhibitor resistance: ROS as critical determinants
por: Bekeschus, Sander
Publicado: (2021)

Transcriptome and N6-Methyladenosine RNA Methylome Analyses in Aortic Dissection and Normal Human Aorta
por: Zhou, Xianwu, et al.
Publicado: (2021)

Microwave ablation with continued EGFR tyrosine kinase inhibitor therapy prolongs disease control in non‐small‐cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors
por: Li, Xin, et al.
Publicado: (2018)

Early On-Treatment Prediction of the Mechanisms of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors
por: Choi, Yu-ra, et al.
Publicado: (2022)

N (6)-Methyladenosine Methylomic Landscape of Lung Tissues in Murine Acute Allergic Asthma
por: Teng, Fangzhou, et al.
Publicado: (2021)

Transcriptome-Wide Map of N(6)-Methyladenosine Methylome Profiling in Human Bladder Cancer
por: Li, Aolin, et al.
Publicado: (2021)

N(6)-Methyladenosine Methylomic Landscape of Ureteral Deficiency in Reflux Uropathy and Obstructive Uropathy
por: Shi, Hua, et al.
Publicado: (2022)

Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer
por: Guo, Renhua, et al.
Publicado: (2011)

Genomic instability as a major mechanism for acquired resistance to EGFR tyrosine kinase inhibitors in cancer
por: Liu, Bing, et al.
Publicado: (2021)

Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
por: James, Angela Joubert, et al.
Publicado: (2020)

The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
por: Wu, Shang-Gin, et al.
Publicado: (2016)

Alteration of N(6)-Methyladenosine mRNA Methylation in a Human Stem Cell-Derived Cardiomyocyte Model of Tyrosine Kinase Inhibitor-Induced Cardiotoxicity
por: Ma, Yan, et al.
Publicado: (2022)

Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity
por: Marcar, Lynnette, et al.
Publicado: (2019)

Neuroendocrine Differentiation in Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
por: Chang, Youjin, et al.
Publicado: (2013)

Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer
por: Ji, Wonjun, et al.
Publicado: (2013)

Acquired Hypothyroidism in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors
por: Wu, Jialu, et al.
Publicado: (2020)

Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors
por: Wagener-Ryczek, Svenja, et al.
Publicado: (2020)

N6-methyladenosine-methylomic landscape of lung tissues of mice with chronic obstructive pulmonary disease
por: Hu, Tingting, et al.
Publicado: (2023)

Correction to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
por: James, Angela Joubert, et al.
Publicado: (2021)

Current understanding of tyrosine kinase BMX in inflammation and its inhibitors
por: Qiu, Le, et al.
Publicado: (2014)

Second-generation inhibitors of Bruton tyrosine kinase
por: Wu, Jingjing, et al.
Publicado: (2016)

Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma
por: Busch, Jonas, et al.
Publicado: (2011)

De novo MET amplification promotes intrinsic resistance to first-generation EGFR tyrosine kinase inhibitors
por: Li, Jing-Wen, et al.
Publicado: (2019)

Protein lysine 43 methylation by EZH1 promotes AML1-ETO transcriptional repression in leukemia
por: Dou, Liping, et al.
Publicado: (2019)

Acquired resistance to tyrosine kinase inhibitors may be linked with the decreased sensitivity to X-ray irradiation
por: Sorokin, Maxim, et al.
Publicado: (2017)

Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors
por: Chen, Justin A., et al.
Publicado: (2020)

Metabolic Plasticity Is an Essential Requirement of Acquired Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia
por: Mostazo, Miriam G. Contreras, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0ndgfme7miul1fj21q1cj8ski0